Targeted therapy in hormone refractory prostate cancer

Despite recent progress in the treatment of hormone refractory prostate cancer—with a survival advantage seen with docetaxel chemotherapy—there remains a need for further improvements in this important patient group. Novel targeted agents have promise both as single agents, and in combination with chemotherapy. However, further work is needed to identify therapeutic targets and to develop active agents with a view to introducing them into standard clinical practice.